Journal
ENDOCRINOLOGY
Volume 162, Issue 11, Pages -Publisher
ENDOCRINE SOC
DOI: 10.1210/endocr/bqab175
Keywords
thiazolidinediones; AAV8-TBGp-Cre; PPAR gamma knockout mouse model; obesity; insulin resistance
Categories
Funding
- National Institutes of Health [K01DK115525]
- Early Career Development Award of the Central Society for Clinical and Translational Research
- UIC start-up funds
- Comunidad de Madrid-Talento Grant [2018-T1/BMD-11966]
- USA ED, 2020 Endocrine Society Summer Research Fellowship [P031C160237]
- VA Merit [BX004448]
Ask authors/readers for more resources
Short-term rosiglitazone maleate treatment can enhance insulin sensitivity but may increase hepatic triglyceride content; in mice with severe obesity, hepatocyte PPAR gamma expression may offset the antisteatogenic actions of TZD.
Thiazolidinediones (TZD) are peroxisome proliferator-activated receptor gamma (PPAR gamma) agonists that may reduce hepatic steatosis through their effects in adipose tissue and therefore have been assessed as potential therapies to treat nonalcoholic fatty liver disease (NAFLD) in humans. However, some studies suggest that expression and activation of hepatocyte PPAR gamma promotes steatosis and that would limit the benefits of TZD as a NAFLD therapy. To further explore this possibility, we examined the impact of short-term rosiglitazone maleate treatment after the development of moderate or severe diet-induced obesity, in both control and adult-onset hepatocyte-specific PPAR gamma knockout (Pparg(Delta Hep)) mice. Independent of the level of obesity and hepatic PPAR gamma expression, the TZD treatment enhanced insulin sensitivity, associated with an increase in white adipose tissue (WAT) fat accumulation, consistent with clinical observations. However, TZD treatment increased hepatic triglyceride content only in control mice with severe obesity. Under these conditions, Pparg(Delta Hep) reduced diet-induced steatosis and prevented the steatogenic effects of short-term TZD treatment. In these mice, subcutaneous WAT was enlarged and associated with increased levels of adiponectin, while hepatic levels of phosphorylated adenosine 5'-monophosphate-activated protein kinase were also increased. In addition, in mice with severe obesity, the expression of hepatic Cd36, Cidea, Cidec, Fabp4, Fasn, and Scd-1 was increased by TZD in a PPAR gamma-dependent manner. Taken together, these results demonstrate that hepatocyte PPAR gamma expression offsets the antisteatogenic actions of TZD in mice with severe obesity. Therefore, in obese and insulin resistant humans, TZD-mediated activation of hepatocyte PPAR gamma may limit the therapeutic potential of TZD to treat NAFLD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available